Fresenius SE & Co. KGaA

FRE

DE0005785604

Healthcare Facilities & Services

Real-time Estimate Tradegate Other stock markets 05:53:23 2024-09-11 am EDT			5-day change	1st Jan Change
33.90 ^EUR	+0.07%		+0.77%	+20.91%

Sep. 09	Hospitals warn of service restrictions	DP
Sep. 02	FRESENIUS SE : DZ Bank reaffirms its Buy rating	ZD

FRESENIUS SE : JP Morgan remains Neutral

July 31, 2024 at 03:30 am EDT

JP Morgan analyst David Adlington maintains his Neutral opinion on the stock. The target price continues to be set at EUR 37.60.

Latest news about Fresenius SE & Co. KGaA

Hospitals warn of service restrictions	Sep. 09	DP
FRESENIUS SE : DZ Bank reaffirms its Buy rating	Sep. 02	ZD
Medical service presents annual statistics on medical errors	Aug. 22	DP
Shelly Group Co-CEO Exits Role as Managing Director of Shelly DACH GmbH	Aug. 20	MT
Lack of blood donations: Reserves almost exhausted	Aug. 17	DP
FRESENIUS SE : Jefferies remains its Buy rating	Aug. 08	ZD
FRESENIUS SE : Receives a Buy rating from Barclays	Aug. 01	ZD
FRESENIUS SE : Warburg Research keeps its Buy rating	Aug. 01	ZD
FRESENIUS : Lots of positives for a strong Q2	Aug. 01
Frankfurt equities close: Cautious optimism ahead of US interest rate decision	Jul. 31	DP
Global markets live: Airbus, HSBC, Boeing, Microsoft, Starbucks...	Jul. 31
Transcript : Fresenius SE & Co. KGaA, Q2 2024 Earnings Call, Jul 31, 2024	Jul. 31
Barclays reads 'Overweight' for Fresenius SE - Target 36.50 euros	Jul. 31	DP
FRESENIUS SE : Gets a Neutral rating from Goldman Sachs	Jul. 31	ZD
FRESENIUS SE : Jefferies remains its Buy rating	Jul. 31	ZD
FRESENIUS SE : Warburg Research reaffirms its Buy rating	Jul. 31	ZD
FRESENIUS SE : Deutsche Bank reaffirms its Buy rating	Jul. 31	ZD
FRESENIUS SE : Barclays remains its Buy rating	Jul. 31	ZD
FRESENIUS SE : Buy rating from Berenberg	Jul. 31	ZD
Fresenius earns significantly more in the quarter - beats expectations	Jul. 31	DP
FRESENIUS SE : JP Morgan remains Neutral	Jul. 31	ZD
Fresenius beats Q2 expectations on strong unit performance, cost savings	Jul. 31	RE
Fresenius SE & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Jul. 30	CI
Weak US growth forecast weighs on FMC - shares down	Jul. 30	DP
Dialysis firm FMC cuts outlook for US treatment volumes, shares fall	Jul. 30	RE

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).

Employees

175,771

Sector

Healthcare Facilities & Services

Calendar

2024-11-05 - Q3 2024 Earnings Call

Related indices

STOXX Europe 600 Index (EUR) , DAX

More about the company